시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
토포이소머라제 I 억제제 시장 보고서(2025년)
Topoisomerase I Inhibitors Global Market Report 2025
상품코드 : 1760728
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,661,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,629,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,596,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

토포이소머라제 I 억제제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 6.0%의 CAGR로 69억 5,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 암 발병률 증가, 연구개발 확대, 암 치료 옵션에 대한 인식 증가, 고령화, 암 연구에 대한 정부 자금 지원 증가 등에 기인할 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 유전체 및 맞춤의료의 발전, 경구용 제제 개발, 병용요법의 효과 향상, 제네릭 의약품 개발, 민관 협력의 증가 등이 있습니다.

암의 유병률 증가는 가까운 장래에 토포이소머라제 I 억제제 시장을 크게 견인할 것으로 예상됩니다. 암은 비정상적인 세포의 무질서한 증식과 확산으로 정의되는 질병군으로 사망을 포함한 심각한 건강 합병증을 유발할 수 있습니다. 암 환자의 증가는 식습관 장애, 운동 부족, 담배 사용과 같은 생활습관 관련 위험요인의 증가와 관련이 있으며, 이 모든 것이 암 발병률 증가에 기여하고 있습니다. 토포이소머라제 I 억제제는 암세포의 DNA 복제 과정을 억제하여 DNA 손상을 일으켜 세포분열을 멈추고 세포 사멸을 유도함으로써 암 치료에 사용됩니다. 예를 들어, 2024년 2월 세계보건기구(WHO)는 2050년까지 3,500만 명 이상의 암 환자가 새로 발생해 2022년 예상했던 2,000만 명에서 77% 증가할 것으로 예측했습니다. 이러한 암 환자 급증은 토포이소머라제 I 억제제 시장 성장에 중요한 촉진제가 될 것입니다.

토포이소머라제 I 억제제 시장의 주요 업체들은 항체의 표적화 능력을 활용하여 약제 내성을 극복하는 항체약물접합체(ADC)와 같은 시장을 개척하는 데 주력하고 있습니다. 암세포에 직접 전달합니다. 예를 들어, 2024년 7월 캐나다에 본사를 둔 생명공학 기업 자이메웍스(Zymeworks)는 미국 식품의약국(FDA)이 ZW191의 임상시험용 신약(IND) 신청을 승인했다고 발표했습니다. 이 혁신적인 ADC는 엽산 수용체 a(FRa)를 표적으로 하는 토포이소머라제 I 억제제(TOPO1i)를 전달하며, ZW191은 첨단 TOPO1i 기반 페이로드 기술인 ZD06519를 통합한 자이메웍스의 독자적인 약물 복합체 플랫폼을 통해 개발됐습니다. ZW191은 주로 난소암 및 기타 부인과 암, 비소세포폐암(NSCLC)을 포함한 FRa 발현 종양을 표적으로 합니다. 이 약은 안전성과 유효성을 최적화하기 위해 8가지 약물 항체 비율(DAR)로 설계되었으며, 내약성과 치료 효과의 균형을 맞추기 위해 노력하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 전략

제36장 부록

ksm
영문 목차

영문목차

Topoisomerase I inhibitors are a class of therapeutic agents that interfere with the activity of topoisomerase I, an enzyme responsible for relieving the torsional strain that occurs during DNA replication and transcription. These inhibitors work by binding to the enzyme-DNA complex, preventing the re-ligation of DNA strands after the enzyme induces a temporary break. Disruption of topoisomerase I activity leads to the accumulation of DNA damage, ultimately resulting in cell death, particularly in rapidly dividing cells.

The main types of topoisomerase I inhibitors include camptothecin derivatives and non-camptothecin-based inhibitors. Camptothecin derivatives are drugs developed from camptothecin, a natural compound extracted from the Chinese tree Camptotheca acuminata. These inhibitors can be administered through oral, injectable, and other routes and are commonly used in hospitals, clinics, and other healthcare settings.

The topoisomerase I inhibitors market research report is one of a series of new reports from The Business Research Company that provides topoisomerase I inhibitors market statistics, including topoisomerase I inhibitors industry global market size, regional shares, competitors with a topoisomerase I inhibitors market share, detailed topoisomerase I inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the topoisomerase I inhibitors industry. This topoisomerase I inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The topoisomerase I inhibitors market size has grown strongly in recent years. It will grow from $5.18 billion in 2024 to $5.49 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be attributed to improvements in healthcare infrastructure, rising global healthcare expenditure, higher cancer diagnosis rates, a growing focus on precision oncology, and increased funding for biotech startups.

The topoisomerase I inhibitors market size is expected to see strong growth in the next few years. It will grow to $6.95 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth during the forecast period can be attributed to the increasing prevalence of cancer, expanding research and development, rising awareness of cancer treatment options, an aging population, and increasing government funding for oncology research. Key trends expected during this period include advancements in genomics and personalized medicine, the development of oral formulations, improved efficacy of combination treatments, the development of generic topoisomerase I inhibitors, and increased public-private collaborations.

The growing prevalence of cancer is expected to significantly boost the topoisomerase I inhibitors market in the near future. Cancer, a group of diseases defined by the uncontrolled growth and spread of abnormal cells, can result in serious health complications, including death. The rise in cancer cases is linked to increasing lifestyle-related risk factors such as poor diet, insufficient physical activity, and tobacco use, all contributing to higher cancer incidence. Topoisomerase I inhibitors are used in cancer treatment by disrupting the DNA replication process in cancer cells, causing DNA damage that halts cell division and induces cell death. For example, in February 2024, the World Health Organization (WHO) projected that by 2050, over 35 million new cancer cases will be diagnosed, a 77% increase from the 20 million expected in 2022. This surge in cancer cases will be a key driver for the growth of the topoisomerase I inhibitors market.

Leading companies in the topoisomerase I inhibitors market are concentrating on developing advanced treatments such as antibody-drug conjugates (ADCs) to overcome drug resistance by leveraging the targeting capabilities of antibodies. ADCs are specialized cancer therapies that attach antibodies to cytotoxic drugs, ensuring that the drug is delivered directly to cancer cells while minimizing damage to healthy tissue. For instance, in July 2024, Zymeworks Inc., a biotechnology company based in Canada, announced that the U.S. Food and Drug Administration (FDA) approved its investigational new drug (IND) application for ZW191. This innovative ADC targets the folate receptor-a (FRa) and delivers a topoisomerase I inhibitor (TOPO1i). ZW191 was developed using the company's proprietary drug conjugate platforms, incorporating the advanced TOPO1i-based payload technology, ZD06519. It primarily targets FRa-expressing tumors, including ovarian and other gynecological cancers, as well as non-small cell lung cancer (NSCLC). The drug was designed with eight drug-antibody ratios (DAR) to optimize safety and efficacy, aiming for a balance of tolerability and therapeutic benefit.

In May 2024, Genmab A/S, a biotechnology company based in Denmark, acquired ProfoundBio for $1.8 billion. This acquisition bolstered Genmab's position in the targeted cancer therapy market, with a particular focus on ovarian and other solid tumors. This move aligns with Genmab's strategy to expand its portfolio of innovative cancer treatments. ProfoundBio, a U.S.-based company, specializes in the manufacturing of topoisomerase I inhibitors.

Major players in the topoisomerase i inhibitors market are Pfizer Inc., Nektar Therapeutics, AstraZeneca PLC, Novartis AG, Fresenius Kabi AG, Merck KGaA, BioNTech SE, Daiichi Sankyo Company Limited, Ipsen Pharma S.A.S., Purdue Pharma L.P., Zymeworks Inc., Sagent Pharmaceuticals Inc., Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Debiopharm Group SA, Harbour BioMed Therapeutics Limited, Bio-Thera Solutions Ltd., Gibson Oncology LLC, TopoGEN Inc., DualityBio Inc., Iksuda Therapeutics Ltd.

North America was the largest region in the topoisomerase I inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in topoisomerase I inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the topoisomerase I inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The topoisomerase I inhibitors market consists of sales of chemotherapy drugs, diagnostic kits, intravenous infusion bags and combination therapy products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Topoisomerase I Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on topoisomerase i inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for topoisomerase i inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The topoisomerase i inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Topoisomerase I Inhibitors Market Characteristics

3. Topoisomerase I Inhibitors Market Trends And Strategies

4. Topoisomerase I Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Topoisomerase I Inhibitors Growth Analysis And Strategic Analysis Framework

6. Topoisomerase I Inhibitors Market Segmentation

7. Topoisomerase I Inhibitors Market Regional And Country Analysis

8. Asia-Pacific Topoisomerase I Inhibitors Market

9. China Topoisomerase I Inhibitors Market

10. India Topoisomerase I Inhibitors Market

11. Japan Topoisomerase I Inhibitors Market

12. Australia Topoisomerase I Inhibitors Market

13. Indonesia Topoisomerase I Inhibitors Market

14. South Korea Topoisomerase I Inhibitors Market

15. Western Europe Topoisomerase I Inhibitors Market

16. UK Topoisomerase I Inhibitors Market

17. Germany Topoisomerase I Inhibitors Market

18. France Topoisomerase I Inhibitors Market

19. Italy Topoisomerase I Inhibitors Market

20. Spain Topoisomerase I Inhibitors Market

21. Eastern Europe Topoisomerase I Inhibitors Market

22. Russia Topoisomerase I Inhibitors Market

23. North America Topoisomerase I Inhibitors Market

24. USA Topoisomerase I Inhibitors Market

25. Canada Topoisomerase I Inhibitors Market

26. South America Topoisomerase I Inhibitors Market

27. Brazil Topoisomerase I Inhibitors Market

28. Middle East Topoisomerase I Inhibitors Market

29. Africa Topoisomerase I Inhibitors Market

30. Topoisomerase I Inhibitors Market Competitive Landscape And Company Profiles

31. Topoisomerase I Inhibitors Market Other Major And Innovative Companies

32. Global Topoisomerase I Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Topoisomerase I Inhibitors Market

34. Recent Developments In The Topoisomerase I Inhibitors Market

35. Topoisomerase I Inhibitors Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기